AKEBIA THERAPEUTICS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
AKEBIA THERAPEUTICS, INC. (AKBA) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $0 for the 12-month period ending 2022-12-31, per its 10-K/A filed 2023-08-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2023-08-28
- AKEBIA THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-12-31 was $0.00.
- AKEBIA THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-09-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- AKEBIA THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2021 was $40.00M, a 33.60% decline from fiscal 2020.
- AKEBIA THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2020 was $60.24M, a 60.65% decline from fiscal 2019.
- AKEBIA THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2019 was $153.11M, a 37.06% decline from fiscal 2018.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $0.00 derived: sum of 2 quarters · filed 2023-08-28 | $0.00 derived: sum of 3 quarters · filed 2023-08-28 | $0.00 10-K/A · filed 2023-08-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 4 quarters · filed 2023-08-28 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2023-08-28 | $0.00 derived: sum of 4 quarters · filed 2023-08-28 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-08-28 | $0.00 derived: sum of 3 quarters · filed 2023-08-28 | $20.00M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $0.00 derived: sum of 2 quarters · filed 2023-08-28 | $20.00M derived: sum of 3 quarters · filed 2023-08-28 | $40.00M 10-K/A · filed 2023-08-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $20.00M derived: sum of 2 quarters · filed 2022-11-03 | $40.00M 10-Q · filed 2022-11-03 | $100.00M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $40.00M 10-Q · filed 2022-08-04 | $100.00M derived: sum of 3 quarters · filed 2023-08-28 | $100.00M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-03-31 | $20.00M 10-Q · filed 2022-05-09 | $80.00M derived: sum of 2 quarters · filed 2023-08-28 | $80.00M derived: sum of 3 quarters · filed 2023-08-28 | $80.00M derived: sum of 4 quarters · filed 2023-08-28 |
| 2020-12-31 | $60.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $60.00M derived: sum of 2 quarters · filed 2023-08-28 | $60.00M derived: sum of 3 quarters · filed 2023-08-28 | $60.24M 10-K/A · filed 2023-08-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $245.00K 10-Q · filed 2021-11-04 | $22.75M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $245.00K 10-Q · filed 2021-08-05 | $22.75M derived: sum of 3 quarters · filed 2022-03-01 | $49.66M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $245.00K 10-Q · filed 2021-05-10 | $22.75M derived: sum of 2 quarters · filed 2022-03-01 | $49.66M derived: sum of 3 quarters · filed 2022-03-01 | $74.66M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $22.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $49.42M derived: sum of 2 quarters · filed 2022-03-01 | $74.42M derived: sum of 3 quarters · filed 2022-03-01 | $153.11M 10-K · filed 2022-03-01 |
| 2019-09-30 | $26.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $51.92M derived: sum of 2 quarters · filed 2020-11-05 | $130.61M 10-Q · filed 2020-11-05 | $193.79M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $103.69M 10-Q · filed 2020-08-10 | $166.87M derived: sum of 3 quarters · filed 2021-02-25 | $224.16M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $78.69M 10-Q · filed 2020-05-05 | $141.87M derived: sum of 2 quarters · filed 2021-02-25 | $199.16M derived: sum of 3 quarters · filed 2021-02-25 | $265.63M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $63.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $120.47M derived: sum of 2 quarters · filed 2021-02-25 | $186.94M derived: sum of 3 quarters · filed 2021-02-25 | $243.27M 10-K · filed 2021-02-25 |
| 2018-09-30 | $57.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $123.76M derived: sum of 2 quarters · filed 2019-11-12 | $180.09M 10-Q · filed 2019-11-12 | $232.22M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $66.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $122.80M 10-Q · filed 2019-08-08 | $174.93M derived: sum of 3 quarters · filed 2020-03-12 | $218.68M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $56.33M 10-Q · filed 2019-05-09 | $108.46M derived: sum of 2 quarters · filed 2020-03-12 | $152.21M derived: sum of 3 quarters · filed 2020-03-12 | $181.84M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $52.13M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $95.88M derived: sum of 2 quarters · filed 2020-03-12 | $125.51M derived: sum of 3 quarters · filed 2020-03-12 | $150.00M 10-K · filed 2020-03-12 |
| 2017-09-30 | $43.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $73.38M derived: sum of 2 quarters · filed 2018-11-08 | $97.87M 10-Q · filed 2018-11-08 | $135.09M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-06-30 | $29.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $54.12M 10-Q · filed 2018-08-08 | $91.34M derived: sum of 3 quarters · filed 2019-03-26 | $151.62M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-03-31 | $24.49M 10-Q · filed 2018-05-09 | $61.72M derived: sum of 2 quarters · filed 2019-03-26 | $121.99M derived: sum of 3 quarters · filed 2019-03-26 | $171.55M derived: sum of 4 quarters · filed 2019-03-26 |
| 2016-12-31 | $37.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $97.50M derived: sum of 2 quarters · filed 2019-03-26 | $147.06M derived: sum of 3 quarters · filed 2019-03-26 | $162.38M 10-K · filed 2019-03-26 |
| 2016-09-30 | $60.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $109.84M derived: sum of 2 quarters · filed 2017-11-08 | $125.15M 10-Q · filed 2017-11-08 | $139.50M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $49.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $64.87M 10-Q · filed 2017-08-08 | $79.23M derived: sum of 3 quarters · filed 2018-03-12 | $93.98M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | $15.31M 10-Q · filed 2017-05-09 | $29.67M derived: sum of 2 quarters · filed 2018-03-12 | $44.42M derived: sum of 3 quarters · filed 2018-03-12 | $69.63M derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | $14.35M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $29.11M derived: sum of 2 quarters · filed 2018-03-12 | $54.32M derived: sum of 3 quarters · filed 2018-03-12 | $63.90M 10-K · filed 2018-03-12 |
| 2015-09-30 | $14.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $39.96M derived: sum of 2 quarters · filed 2016-11-09 | $49.55M 10-Q · filed 2016-11-09 | $55.14M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | $25.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $34.79M 10-Q · filed 2016-08-08 | $40.38M derived: sum of 3 quarters · filed 2017-03-06 | $40.63M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | $9.59M 10-Q · filed 2016-05-05 | $15.18M derived: sum of 2 quarters · filed 2017-03-06 | $15.43M derived: sum of 3 quarters · filed 2017-03-06 | $16.67M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | $5.59M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $5.84M derived: sum of 2 quarters · filed 2017-03-06 | $7.08M derived: sum of 3 quarters · filed 2017-03-06 | $12.59M 10-K · filed 2017-03-06 |
| 2014-09-30 | $245.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $1.49M derived: sum of 2 quarters · filed 2015-11-09 | $6.99M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $6.75M 10-Q · filed 2015-08-11 | ||
| 2014-03-31 | $5.50M 10-Q · filed 2015-05-11 | |||
| 2013-12-31 | $1.99M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |